West Orange, NJ – Spectrum360 is pleased to announce the appointment of Marla Weetall to its Board of Trustees. 

This appointment is the newest addition to Spectrum360’s leadership since the implementation of the organization’s three-year strategic plan which included strengthening the board operations and governance.

“Marla’s extensive knowledge and experience make her an invaluable asset to our team,” shared Ken Beger, CEO. “Her ability to track results and assess performance will significantly enhance our operations. We’re thrilled to welcome her aboard.”

Weetall brings a wealth of expertise to the Board. As Senior Vice President of Pharmacology and Biomarkers at PTC Pharmaceuticals, she has dedicated her career to the research and development of innovative treatments in multiple therapeutic areas including neurodevelopmental disorders. Her passion for making a positive impact on the lives of individuals with neurodevelopmental disorders aligns perfectly with Spectrum360’s mission.

“I’m thrilled to join Spectrum360, an organization that has demonstrated a remarkable ability to sustain and grow its services for individuals with autism. I’m eager to contribute my expertise and support their mission.”

Spectrum360 Board of Trustees has fourteen active board members to support its educational, therapeutic and skills-based programs.

###

About Spectrum360:

Spectrum360 is a non-profit leader in special education and adult services for people with autism and those with related challenges. For more than 60 years our schools and adult program have provided the education, socialization and therapeutic supports they need to realize their aspirations, lead thriving lives, and fully engage with their families and in their communities. For more information, visit us at https://spectrum360.org/mission-and-values/.

For Media Inquiries, please contact:

Contact: Melissa Kuper

Email: mkuper@spectrum360.org | Phone: 973-509-3050 x271